文献速递泌尿生殖腹部MRPETCT

前列腺MRI与PSMA-PET/CT之间的不一致:原发性前列腺肿瘤评估的下一个重大挑战?

Discordance between prostate MRI and PSMA-PET/CT: the next big challenge for primary prostate tumor assessment?
PubMed 文献 · Eur Radiol · 2025-01-24

回顾性纳入2021至2023年309例中高危前列腺癌患者,均行MRI与PSMA-PET/CT检查。MRI与PSMA-PET/CT在50.8%(157/309)患者中一致、49.1%(152/309)不一致,其中主要不一致占25.7%(39/152)。仅单一模态可见的病灶中80.0%(36/45)为临床显著前列腺癌。

要点

  • MRI与PSMA-PET/CT评估原发前列腺肿瘤时约半数患者不一致,主要不一致约每8例中1例。
  • 仅MRI可见病灶中85.2%(23/27)为临床显著前列腺癌,仅PSMA-PET/CT可见病灶中78.3%(18/23)为临床显著前列腺癌。
  • 两种模态联合评估可提供互补信息,可能对治疗计划产生实质影响。

核心结论

  • MRI与PSMA-PET/CT在原发性前列腺癌评估中约半数患者不一致,主要不一致约每8例中1例;仅单一模态可见的病灶多数为临床显著前列腺癌。

研究设计与样本

  • 回顾性纳入2021至2023年连续诊断的中高危前列腺癌男性患者309例,中位年龄69岁(IQR 64-75),均行MRI与PSMA-PET/CT检查。MRI采用PI-RADS v2.1、PSMA-PET/CT采用PRIMARY评分解读,以根治性前列腺切除或活检标本作为参考标准进行核对。

关键影像表现/征象

  • MRI与PSMA-PET/CT一致157/309(50.8%),不一致152/309(49.1%)。
  • 不一致中主要不一致39/152(25.7%),次要不一致113/152(74.3%)。
  • 仅MRI可见病灶27例中85.2%(23/27)为临床显著前列腺癌。
  • 仅PSMA-PET/CT可见病灶23例中78.3%(18/23)为临床显著前列腺癌。
  • 仅单一模态可见的病灶合计45例,其中80.0%(36/45)为临床显著前列腺癌。

诊断标准与关键数值

  • MRI采用PI-RADS v2.1评分,PSMA-PET/CT采用PRIMARY评分。
  • 不一致分为「次要」(一种模态可见更大或额外病灶)与「主要」(仅一种模态阳性或两种模态指示病灶不同)。
  • 以根治性前列腺切除或活检标本作为参考标准核对不一致。
  • 仅MRI可见病灶中临床显著前列腺癌占85.2%(23/27),仅PSMA-PET/CT可见病灶中占78.3%(18/23)。
  • 仅单一模态可见病灶中临床显著前列腺癌占80.0%(36/45)。

临床应用与阅片要点

  • 中高危前列腺癌患者接受MRI与PSMA-PET/CT评估时,约半数存在不一致。
  • 仅单一模态可见的病灶多数为临床显著前列腺癌,两种模态联合可提供互补信息。
  • 作者指出两种模态联合用于原发前列腺肿瘤评估可能对治疗计划产生实质影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: An increasing number of patients with prostate cancer (PCa) undergo assessment with magnetic resonance imaging (MRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT). This offers comprehensive multimodality staging but can lead to discrepancies. The objective was to assess the rates and types of discordance between MRI and PSMA-PET/CT for primary PCa assessment.

MATERIALS AND METHODS: Consecutive men diagnosed with intermediate and high-risk PCa who underwent MRI and PSMA-PET/CT in 2021-2023 were retrospectively included. MRI and PSMA-PET/CT were interpreted using PI-RADS v2.1 and PRIMARY scores. Discordances between the two imaging modalities were categorized as "minor" (larger or additional lesion seen on one modality) or "major" (positive on only one modality or different index lesions between MRI and PSMA-PET/CT) and reconciled using radical prostatectomy or biopsy specimens.

RESULTS: Three hundred and nine men (median age 69 years, interquartile range (IQR) 64-75) were included. Most had Gleason Grade Group ≥ 3 PCa (70.9% (219/309)). Median PSA was 9.0 ng/mL (IQR 5.6-13.6). MRI and PSMA-PET/CT were concordant in 157/309 (50.8%) and discordant in 152/309 (49.1%) patients; with 39/152 (25.7%) major and 113/152 (74.3%) minor discordances. Of 27 patients with lesions only seen on MRI, 85.2% (23/27) were clinically significant PCa (csPCa). Of 23 patients with lesions only seen on PSMA-PET/CT, 78.3% (18/23) were csPCa. Altogether, lesions seen on only one modality were csPCa in 80.0% (36/45).

CONCLUSION: MRI and PSMA-PET/CT were discordant in half of patients for primary PCa evaluation, with major discrepancies seen in roughly one out of eight patients.

KEY POINTS: Question While both MRI and PSMA-PET/CT can be used for primary tumor assessment, the discordances between them are not well established. Findings MRI and PSMA-PET/CT were discordant in about half of the patients. Most prostate lesions seen on only one modality were significant cancer. Clinical relevance MRI and PSMA-PET/CT are often discordant for assessing the primary prostate tumor. Using both modalities for primary prostate tumor evaluation can provide complementary information that may substantially impact treatment planning.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Woo S, Becker AS, Leithner D, et al. Discordance between prostate MRI and PSMA-PET/CT: the next big challenge for primary prostate tumor assessment? Eur Radiol. 2025. PMID: 39853335. doi:10.1007/s00330-025-11358-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。